AVTR
Avantor Inc.
Is AVTR Halal?
Life sciences supplies — laboratory products for research.
What You Should Know
Avantor provides life science materials and lab supplies. Core business serves medical and scientific research (permissible). Its March 31, 2026 filing shows 32.72% debt/assets, 2.39% liquidity/assets, 11.87% receivables-plus-cash/assets and 0.66% disclosed interest income/net sales; activity allocation remains incomplete.
⚠️ Concerns
- •Higher debt from acquisitions
- •Minor interest income
- •Pharmaceutical, clinical and laboratory end-use allocation is not separately disclosed
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
3,816.3 / 11,663
279.3 / 11,663
1,384.1 / 11,663
10.5 / 1,581.4
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 32.72%, liquidity/assets is 2.39%, receivables-plus-cash/assets is 11.87% and disclosed interest income is 0.66%; examined financial ratios pass, but activity allocation remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt, liquidity and receivables-plus-cash are below the examined total-assets limits; life-science activity remains incompletely allocated. This is not an index-membership claim.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets and identifiable conventional liquidity are below the examined Malaysia limits; activity allocation remains incomplete.
- Financial
- Not calculated
- Overall
- Incomplete
A properly licensed and reproducible historical market-cap series is not stored.
Business-activity disclosure
Avantor supplies life-science materials, laboratory products and services. The retained qualitative analysis treats the core activity as generally permissible while noting pharmaceutical, clinical, chemical and customer end-use questions.
Limitation: No universal prohibited-revenue allocation is inferred from product, customer or end-market disclosures.
Purification
Disclosed interest income is 0.66% of quarterly net sales, but no scholar-approved purification percentage is asserted for life-science supplies.
Inputs, assumptions and primary sources
- Amounts are USD millions from Avantor's March 31, 2026 Form 10-Q.
- Debt is $37.0 million current debt plus $3,779.3 million debt net of current portion; operating leases are excluded. Cash is $279.3 million and no separately identified interest-bearing securities are added.
- Accounts receivable is $1,104.8 million and quarterly net sales are $1,581.4 million. The filing discloses $10.5 million of interest income, primarily from cross-currency swaps.
- The filing does not provide a scholar-universal prohibited-revenue numerator for laboratory, pharmaceutical, clinical or customer end uses.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →